Decade trends in risk factors,treatments,and prognosis of minor ischemic stroke and TIA in China

Abstract

Background:

Real-world data on the long-term trends in risk factors, acute antithrombotic strategies, medication adherence, and their impact on the prognosis of minor ischemic stroke (MIS) or transient ischemic attack (TIA) are limited.

Methods:

We analyzed cases of acute MIS (National Institutes of Health Stroke Scale score ⩽ 3) and TIA from the China National Stroke Registries (CNSRs), a series of multicenter, nationwide hospital-based registries in China. Stroke risk factors, acute antithrombotic strategies, and adherence to secondary prevention were compared between CNSR I (2007–2008) and CNSR III (2015–2018). The main outcomes were stroke recurrence, disability (modified Rankin Scale 3–5), and all-cause mortality at 3, 6, and 12 months of follow-up.

Results:

In total, 15,352 patients with acute MIS or TIA were included, including 7,013 patients from CNSR I and 8,339 patients from CNSR III. Over the past decade, there has been a 10-fold increase in the acute use of dual antiplatelet therapy (3.15% in CNSR I vs 31.75% in CNSR III) and a seven-fold increase in statin adherence at the 12 month follow-up (10.56% in CNSR I vs 71.15% in CNSR III). It was also observed that the adjusted cumulative incidence of stroke recurrence (15.38% [15.29%–15.47%] vs 8.29% [8.27%–8.32%]), disability rates (11.29% [11.12%–11.46%] vs 4.38% [4.32%–4.44%]), and all-cause mortality (8.17% [8.04%–8.30%] vs 1.86% [1.83%–1.89%]) at the 12-month follow-up showed a marked decline over the decade. Risk factors such as age (per 10 years), diabetes, and prior stroke were linked to a higher risk of 12-month stroke recurrence in CNSR I (CNSR I: odds ratio (OR) and 95% confidence interval (CI), 1.25 [1.17–1.33] for age per 10 years; 1.40 [1.18–1.66] for diabetes; and 1.96 [1.68–2.27] for prior stroke), and these associations remained significant after 10 years (CNSR III: OR and 95% CI, 1.15 [1.08–1.24] for age per 10 years; 1.35 [1.13–1.61] for diabetes; and 1.54 [1.29–1.84] for prior stroke).

Conclusion:

The past decade has witnessed significant advancements in both acute antithrombotic strategies and medication adherence, accompanied by marked reductions in stroke recurrence, disability, and mortality. These improvements highlight a positive shift toward more effective evidence-based care for patients with MIS or TIA.

Graphical abstract

Keywords

Minor ischemic stroke transient ischemic attack risk factors antithrombotic strategies medication adherence prognosis

Get full access to this article

View all access options for this article.

References

Xian

Matsouaka

, et al. Analysis of prescriptions for dual antiplatelet therapy after acute ischemic stroke. JAMA Netw Open 2022; 5: e2224157.

Amarenco

Lavallée

Labreuche

, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016; 374: 1533–1542.

Amarenco

Lavallée

Monteiro Tavares

, et al. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 2018; 378: 2182–2190.

Hobeanu

Lavallée

Charles

, et al. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study. Lancet Neurol 2022; 21: 889–898.

Wang

Zhao

, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

Johnston

Easton

Farrant

, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215–225.

Johnston

Amarenco

Denison

, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383: 207–217.

Wang

Meng

Wang

, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med 2021; 385: 2520–2530.

Paciaroni

Agnelli

Falocci

, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 2015; 46: 2175–2182.

10.

Brott

Hobson

2nd Howard

, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11–23.

11.

Powers

Rabinstein

Ackerson

, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49: e46–e110.

12.

Warner

Harrington

Sacco

Elkind

MSV

. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. Stroke 2019; 50: 3331–3332.

13.

Dawson

Merwick Webb

ÁA

, et al. European stroke organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J 2021; 6: ClXXXVII–CXCI.

14.

Del Brutto

Yin

Gardener

, et al. Determinants and temporal trends of dual antiplatelet therapy after mild noncardioembolic stroke. Stroke 2023; 54: 2552–2561.

15.

Lendaris

Lessen

Cheng

, et al. Under treatment of high-risk TIA patients with clopidogrel-aspirin in the emergency setting. J Stroke Cerebrovasc Dis 2021; 30: 106145.

16.

De Matteis

De Santis

Ornello

, et al. Divergence between clinical trial evidence and actual practice in use of dual antiplatelet therapy after transient ischemic attack and minor stroke. Stroke 2023; 54: 1172–1181.

17.

Dalli

Kim

Cadilhac

, et al. Greater adherence to secondary prevention medications improves survival after stroke or transient ischemic attack: a linked registry study. Stroke 2021; 52: 3569–3577.

18.

Dalli

Kim

Thrift

, et al. Patterns of use and discontinuation of secondary prevention medications after stroke. Neurology 2021; 96: e30–e41.

19.

Wang

Cui

, et al. The China national stroke registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011; 6: 355–361.

20.

Wang

Jing

Meng

, et al. The third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke Vasc Neurol 2019; 4: 158–164.

21.

McArthur

Quinn

Dawson

Walters

MR.

Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase. BMJ 2011; 342: d1938.

22.

Lioutas

Ivan

Himali

, et al. Incidence of transient ischemic attack and association with long-term risk of stroke. JAMA 2021; 325: 373–381.

23.

von Elm

Altman

Egger

, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.

24.

Shahjouei

Sadighi

Chaudhary

, et al. A 5-decade analysis of incidence trends of ischemic stroke after transient ischemic attack: a systematic review and meta-analysis. JAMA Neurol 2021; 78: 77–87.

25.

Sundararajan

Thrift

Phan

Choi

Clissold

Srikanth

VK.

Trends over time in the risk of stroke after an incident transient ischemic attack. Stroke 2014; 45: 3214–3218.

26.

Edwards

Kapral

Fang

Swartz

RH.

Trends in long-term mortality and morbidity in patients with no early complications after stroke and transient ischemic attack. J Stroke Cerebrovasc Dis 2017; 26: 1641–1645.

27.

Kernan

Ovbiagele

Black

, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160–2236.

28.

Fonseca

Merwick

Dennis

, et al. European stroke organisation (ESO) guidelines on management of transient ischaemic attack. Eur Stroke J 2021; 6: CLXIII–CLXXXVI.

29.

Bath

Woodhouse

Appleton

, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet 2018; 391: 850–859.

30.

Khatri

Kleindorfer

Devlin

, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA 2018; 320: 156–166.

31.

Coutts

Ankolekar

Appireddy

, et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet 2024; 403: 2597–2605.

32.

Wang

Liu

, et al. Trend of declining stroke mortality in China: reasons and analysis. Stroke Vasc Neurol 2017; 2: 132–139.